Skip to Content

Gammaplex (immune globulin intravenous) Disease Interactions

There are 3 disease interactions with Gammaplex (immune globulin intravenous):


Immune Globulin Intravenous (Includes Gammaplex) ↔ Hfi

Severe Potential Hazard, Moderate plausibility

Applies to: Fructose Intolerance

The immune globulin intravenous (human) injection, Flebogamma 10% DIF and Gammaplex contain sorbitol and should not be administered to patients with hereditary fructose intolerance (HFI).


Immune Globulin Intravenous (Includes Gammaplex) ↔ Renal Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction, Sepsis

Renal abnormalities such as acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, including acute renal dysfunction/failure and death have been reported after immune globulin intravenous (IGIV) products. Cases of renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose as a stabilizer. Ensure that patients are not volume-depleted before administering these agents and assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before initiating the infusion and at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation of the product. Periodic monitoring of renal function and urine output is important in patients at increased risk of developing acute renal failure. Administer these agents at the minimum dose and rate of infusion practicable in patients at risk for renal dysfunction or failure.


Immune Globulin Intravenous (Includes Gammaplex) ↔ Thrombosis

Severe Potential Hazard, Moderate plausibility

Applies to: Diabetes Mellitus, Cardiovascular Disease, History - Thrombotic/Thromboembolic Disorder, Polycythemia, Hyponatremia

Thrombosis has been reported after treatment with immune globulin products. In general, patients at greatest risk of thromboembolic events are those of advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors; therefore, it is recommended that patients treated with these agents should be monitored for signs and symptoms of thrombosis and assess blood viscosity in patients at risk. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity,

Gammaplex (immune globulin intravenous) drug Interactions

There are 173 drug interactions with Gammaplex (immune globulin intravenous)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.